

S Moein Moghimi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7581674/publications.pdf>

Version: 2024-02-01

228
papers

20,024
citations

13865
67
h-index

11052
137
g-index

237
all docs

237
docs citations

237
times ranked

21469
citing authors

#	ARTICLE	IF	CITATIONS
1	Cell medium-dependent dynamic modulation of size and structural transformations of binary phospholipid/1-3 fatty acid liquid crystalline nano-self-assemblies: Implications in interpretation of cell uptake studies. <i>Journal of Colloid and Interface Science</i> , 2022, 606, 464-479.	9.4	8
2	Use of “nano” prefix is no small matter. <i>Nature</i> , 2022, , .	27.8	1
3	Critical issues and pitfalls in serum and plasma handling for complement analysis in nanomedicine and bionanotechnology. <i>Nano Today</i> , 2022, 44, 101479.	11.9	10
4	Pro-inflammatory concerns with lipid nanoparticles. <i>Molecular Therapy</i> , 2022, 30, 2109-2110.	8.2	16
5	Antibody-Dependent Complement Responses toward SARS-CoV-2 Receptor-Binding Domain Immobilized on “Pseudovirus-like” Nanoparticles. <i>ACS Nano</i> , 2022, , .	14.6	7
6	A structurally diverse library of glycerol monooleate/oleic acid non-lamellar liquid crystalline nanodispersions stabilized with nonionic methoxypoly(ethylene glycol) (mPEG)-lipids showing variable complement activation properties. <i>Journal of Colloid and Interface Science</i> , 2021, 582, 906-917.	9.4	21
7	Editorial: Immune Mechanisms in the Pathologic Response to Particles, Fibers, and Nanomaterials. <i>Frontiers in Immunology</i> , 2021, 12, 665810.	4.8	0
8	Allergic Reactions and Anaphylaxis to LNP-Based COVID-19 Vaccines. <i>Molecular Therapy</i> , 2021, 29, 898-900.	8.2	91
9	Integrin-Targeted, Short Interfering RNA Nanocomplexes for Neuroblastoma Tumor-Specific Delivery Achieve MYCN Silencing with Improved Survival. <i>Advanced Functional Materials</i> , 2021, 31, 2104843.	14.9	12
10	Dendrimer end-terminal motif-dependent evasion of human complement and complement activation through IgM hitchhiking. <i>Nature Communications</i> , 2021, 12, 4858.	12.8	14
11	Microneedle-based devices for point-of-care infectious disease diagnostics. <i>Acta Pharmaceutica Sinica B</i> , 2021, 11, 2344-2361.	12.0	35
12	Complement opsonization of nanoparticles: Differences between humans and preclinical species. <i>Journal of Controlled Release</i> , 2021, 338, 548-556.	9.9	20
13	Roadmap on nanomedicine. <i>Nanotechnology</i> , 2021, 32, 012001.	2.6	17
14	Non-Lamellar Liquid Crystalline Nanocarriers for Thymoquinone Encapsulation. <i>Molecules</i> , 2020, 25, 16.	3.8	30
15	Airborne Particulate Matter and SARS-CoV-2 Partnership: Virus Hitchhiking, Stabilization and Immune Cell Targeting “A Hypothesis. <i>Frontiers in Immunology</i> , 2020, 11, 579352.	4.8	16
16	The Journal of Nanotheranostics: A New Open-Access Journal at the Interface of Nanotechnology, Materials Science, and Medicine for Precision Medicine. <i>Journal of Nanotheranostics</i> , 2020, 1, 56-57.	3.1	0
17	Complement activation by drug carriers and particulate pharmaceuticals: Principles, challenges and opportunities. <i>Advanced Drug Delivery Reviews</i> , 2020, 157, 83-95.	13.7	39
18	A rally for brain targeting: the advent of a new era. <i>Therapeutic Delivery</i> , 2020, 11, 465-470.	2.2	3

#	ARTICLE	IF	CITATIONS
19	Hexosome engineering for targeting of regional lymph nodes. <i>Materialia</i> , 2020, 11, 100705.	2.7	17
20	Tuning the Engines of Nanomedicine. <i>Molecular Therapy</i> , 2020, 28, 693-694.	8.2	4
21	Overcoming Nanoparticle-Mediated Complement Activation by Surface PEG Pairing. <i>Nano Letters</i> , 2020, 20, 4312-4321.	9.1	70
22	Complement Activation by Nanomaterials. <i>Molecular and Integrative Toxicology</i> , 2020, , 83-98.	0.5	3
23	Elevated circulating endothelin-1 as a potential biomarker for high-risk COVID-19 severity. <i>Precision Nanomedicine</i> , 2020, 3, .	0.8	8
24	The diagnostic potential of microneedles in infectious diseases. <i>Precision Nanomedicine</i> , 2020, 3, .	0.8	2
25	Reprogramming the lymphocyte axis for advanced immunotherapy. <i>Advanced Drug Delivery Reviews</i> , 2019, 141, 1-2.	13.7	0
26	Perturbation of mitochondrial bioenergetics by polycations counteracts resistance to BRAFE600 inhibition in melanoma cells. <i>Journal of Controlled Release</i> , 2019, 309, 158-172.	9.9	3
27	On the issue of transparency and reproducibility in nanomedicine. <i>Nature Nanotechnology</i> , 2019, 14, 629-635.	31.5	149
28	Crossing the blood-brain-barrier with nanoligand drug carriers self-assembled from a phage display peptide. <i>Nature Communications</i> , 2019, 10, 4635.	12.8	98
29	CAR T-cell bioengineering: Single variable domain of heavy chain antibody targeted CARs. <i>Advanced Drug Delivery Reviews</i> , 2019, 141, 41-46.	13.7	29
30	Determination of Polycation-Mediated Perturbation of Mitochondrial Respiration in Intact Cells by High-Resolution Respirometry (Oxygraph-2k, OROBOROS). <i>Methods in Molecular Biology</i> , 2019, 1943, 313-322.	0.9	8
31	Lactate Dehydrogenase Assay for Assessment of Polycation Cytotoxicity. <i>Methods in Molecular Biology</i> , 2019, 1943, 291-299.	0.9	21
32	Combined Fluorimetric Caspase-3/7 Assay and Bradford Protein Determination for Assessment of Polycation-Mediated Cytotoxicity. <i>Methods in Molecular Biology</i> , 2019, 1943, 301-311.	0.9	0
33	Complement therapeutics meets nanomedicine: overcoming human complement activation and leukocyte uptake of nanomedicines with soluble domains of CD55. <i>Journal of Controlled Release</i> , 2019, 302, 181-189.	9.9	24
34	The Interplay Between Blood Proteins, Complement, and Macrophages on Nanomedicine Performance and Responses. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2019, 370, 581-592.	2.5	47
35	Pharmacokinetic analysis reveals limitations and opportunities for nanomedicine targeting of endothelial and extravascular compartments of tumours. <i>Journal of Drug Targeting</i> , 2019, 27, 690-698.	4.4	15
36	Immunoglobulin deposition on biomolecule corona determines complement opsonization efficiency of preclinical and clinical nanoparticles. <i>Nature Nanotechnology</i> , 2019, 14, 260-268.	31.5	204

#	ARTICLE	IF	CITATIONS
37	Targeting Biological Barriers: Turning a Wall into a Therapeutic Springboard. <i>Molecular Therapy</i> , 2018, 26, 933-934.	8.2	7
38	Nanomedicine safety in preclinical and clinical development: focus on idiosyncratic injection/infusion reactions. <i>Drug Discovery Today</i> , 2018, 23, 1034-1042.	6.4	58
39	Translational gaps in animal models of human infusion reactions to nanomedicines. <i>Nanomedicine</i> , 2018, 13, 973-975.	3.3	23
40	Cisplatin Encapsulation Generates Morphologically Different Multicompartment in the Internal Nanostructures of Nonlamellar Liquid-Crystalline Self-Assemblies. <i>Langmuir</i> , 2018, 34, 6570-6581.	3.5	33
41	Multivalent targeting and killing of HER2 overexpressing breast carcinoma cells with methotrexate-encapsulated tetra-specific non-overlapping variable domain heavy chain anti-HER2 antibody-PEG-liposomes: In vitro proof-of-concept. <i>European Journal of Pharmaceutical Sciences</i> , 2018, 122, 42-50.	4.0	23
42	Nanoparticle transport pathways into tumors. <i>Journal of Nanoparticle Research</i> , 2018, 20, 169.	1.9	50
43	C1q-Mediated Complement Activation and C3 Opsonization Trigger Recognition of Stealth Poly(2-methyl-2-oxazoline)-Coated Silica Nanoparticles by Human Phagocytes. <i>ACS Nano</i> , 2018, 12, 5834-5847.	14.6	86
44	Skin Biosensing and Bioanalysis: what the Future Holds. <i>Precision Nanomedicine</i> , 2018, 1, 124-127.	0.8	3
45	Smart polymers in drug delivery: a biological perspective. <i>Polymer Chemistry</i> , 2017, 8, 41-51.	3.9	55
46	Peptide and nucleic acid-directed self-assembly of cationic nanovehicles through giant unilamellar vesicle modification: Targetable nanocomplexes for in vivo nucleic acid delivery. <i>Acta Biomaterialia</i> , 2017, 51, 351-362.	8.3	28
47	Polyplex Evolution: Understanding Biology, Optimizing Performance. <i>Molecular Therapy</i> , 2017, 25, 1476-1490.	8.2	146
48	Bypassing adverse injection reactions to nanoparticles through shape modification and attachment to erythrocytes. <i>Nature Nanotechnology</i> , 2017, 12, 589-594.	31.5	154
49	Complement activation turnover on surfaces of nanoparticles. <i>Nano Today</i> , 2017, 15, 8-10.	11.9	67
50	Nanoparticle Technology: Having Impact, but Needing Further Optimization. <i>Molecular Therapy</i> , 2017, 25, 1461-1463.	8.2	4
51	Poly-(amidoamine) dendrimers with a precisely core positioned sulforhodamine B molecule for comparative biological tracing and profiling. <i>Journal of Controlled Release</i> , 2017, 246, 88-97.	9.9	18
52	Complement proteins bind to nanoparticle protein corona and undergo dynamic exchange in vivo. <i>Nature Nanotechnology</i> , 2017, 12, 387-393.	31.5	411
53	Revealing Dynamics of Accumulation of Systemically Injected Liposomes in the Skin by Intravital Microscopy. <i>ACS Nano</i> , 2017, 11, 11584-11593.	14.6	21
54	Interaction of extremophilic archaeal viruses with human and mouse complement system and viral biodistribution in mice. <i>Molecular Immunology</i> , 2017, 90, 273-279.	2.2	5

#	ARTICLE	IF	CITATIONS
55	Nanoparticles and innate immunity: new perspectives on host defence. <i>Seminars in Immunology</i> , 2017, 34, 33-51.	5.6	244
56	ImmunoPEGliposome-mediated reduction of blood and brain amyloid levels in a mouse model of Alzheimer's disease is restricted to aged animals. <i>Biomaterials</i> , 2017, 112, 141-152.	11.4	32
57	In Vitro and In Vivo Differences in Murine Third Complement Component (C3) Opsonization and Macrophage/Leukocyte Responses to Antibody-Functionalized Iron Oxide Nanoworms. <i>Frontiers in Immunology</i> , 2017, 8, 151.	4.8	40
58	Theranostics. , 2017, , 4505-4507.		1
59	Editorial: Interaction Between the Immune System and Nanomaterials: Safety and Medical Exploitation. <i>Current Bionanotechnology</i> , 2016, 2, 3-5.	0.6	5
60	Activation of Human Complement System by Dextran-Coated Iron Oxide Nanoparticles Is Not Affected by Dextran/Fe Ratio, Hydroxyl Modifications, and Crosslinking. <i>Frontiers in Immunology</i> , 2016, 7, 418.	4.8	43
61	Nanoparticle patterning for biomedicine. <i>BiolImpacts</i> , 2016, 6, 183-185.	1.5	3
62	Recognition of extremophilic archaeal viruses by eukaryotic cells: a promising nanoplatfrom from the third domain of life. <i>Scientific Reports</i> , 2016, 6, 37966.	3.3	5
63	Call for papers: Nanoparticle Development and Applications in Cellular and Molecular Therapies. <i>Molecular Therapy</i> , 2016, 24, 1334-1335.	8.2	3
64	A structurally diverse library of safe-by-design citrem-phospholipid lamellar and non-lamellar liquid crystalline nano-assemblies. <i>Journal of Controlled Release</i> , 2016, 239, 1-9.	9.9	76
65	AFM visualization of sub-50 nm polyplex disposition to the nuclear pore complex without compromising the integrity of the nuclear envelope. <i>Journal of Controlled Release</i> , 2016, 244, 24-29.	9.9	16
66	The Art of Complement: Complement Sensing of Nanoparticles and Consequences. <i>Advances in Delivery Science and Technology</i> , 2016, , 43-51.	0.4	3
67	Soluble and immobilized graphene oxide activates complement system differently dependent on surface oxidation state. <i>Biomaterials</i> , 2016, 78, 20-26.	11.4	35
68	Complement Propriety and Conspiracy in Nanomedicine: Perspective and a Hypothesis. <i>Nucleic Acid Therapeutics</i> , 2016, 26, 67-72.	3.6	15
69	An integrated assessment of morphology, size, and complement activation of the PEGylated liposomal doxorubicin products DoxilÂ®, CaelyxÂ®, DOXOrubicin, and SinaDoxosome. <i>Journal of Controlled Release</i> , 2016, 221, 1-8.	9.9	152
70	Platelet mimicry: The emperor's new clothes?. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2016, 12, 245-248.	3.3	19
71	Liposomes. , 2016, , 1802-1808.		0
72	Tumour exosomes display differential mechanical and complement activation properties dependent on malignant state: implications in endothelial leakiness. <i>Journal of Extracellular Vesicles</i> , 2015, 4, 29685.	12.2	86

#	ARTICLE	IF	CITATIONS
73	Insidious pathogen-mimicking properties of nanoparticles in triggering the lectin pathway of the complement system. <i>European Journal of Nanomedicine</i> , 2015, 7, .	0.6	6
74	Modulatory Effect of Human Plasma on the Internal Nanostructure and Size Characteristics of Liquid-Crystalline Nanocarriers. <i>Langmuir</i> , 2015, 31, 5042-5049.	3.5	59
75	Cubosomes and hexosomes as versatile platforms for drug delivery. <i>Therapeutic Delivery</i> , 2015, 6, 1347-1364.	2.2	130
76	Polyethylenimine architecture-dependent metabolic imprints and perturbation of cellular redox homeostasis. <i>Biochimica Et Biophysica Acta - Bioenergetics</i> , 2015, 1847, 328-342.	1.0	28
77	Dendrimers in Medicine: Therapeutic Concepts and Pharmaceutical Challenges. <i>Bioconjugate Chemistry</i> , 2015, 26, 1198-1211.	3.6	193
78	Differential Modulation of Cellular Bioenergetics by Poly(ϵ -lysine)s of Different Molecular Weights. <i>Biomacromolecules</i> , 2015, 16, 2119-2126.	5.4	24
79	New platforms for multi-functional ocular lenses: engineering double-sided functionalized nano-coatings. <i>Journal of Drug Targeting</i> , 2015, 23, 305-310.	4.4	16
80	Citrem modulates internal nanostructure of glyceryl monooleate dispersions and bypasses complement activation: Towards development of safe tunable intravenous lipid nanocarriers. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2015, 11, 1909-1914.	3.3	64
81	Modulatory Role of Surface Coating of Superparamagnetic Iron Oxide Nanoworms in Complement Opsonization and Leukocyte Uptake. <i>ACS Nano</i> , 2015, 9, 10758-10768.	14.6	82
82	Repeated intraperitoneal injections of liposomes containing phosphatidic acid and cardiolipin reduce amyloid- β levels in APP/PS1 transgenic mice. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2015, 11, 421-430.	3.3	68
83	Recent Advances in Cryo-TEM Imaging of Soft Lipid Nanoparticles. <i>AIMS Biophysics</i> , 2015, 2, 116-130.	0.6	45
84	Polycation-Mediated Integrated Cell Death Processes. <i>Advances in Genetics</i> , 2014, 88, 353-398.	1.8	21
85	Poly(3-hydroxybutyrate- ϵ -caprolactone-3-hydroxyhexanoate) Nanoparticles with Polyethylenimine Coat as Simple, Safe, and Versatile Vehicles for Cell Targeting: Population Characteristics, Cell Uptake, and Intracellular Trafficking. <i>Advanced Healthcare Materials</i> , 2014, 3, 817-824.	7.6	41
86	Mechanisms of complement activation by dextran-coated superparamagnetic iron oxide (SPIO) nanoworms in mouse versus human serum. <i>Particle and Fibre Toxicology</i> , 2014, 11, 64.	6.2	79
87	Cancer nanomedicine and the complement system activation paradigm: Anaphylaxis and tumour growth. <i>Journal of Controlled Release</i> , 2014, 190, 556-562.	9.9	82
88	Nanoparticles in Medicine. , 2014, , 77-89.		5
89	T cells expressing VHH-directed oligoclonal chimeric HER2 antigen receptors: Towards tumor-directed oligoclonal T cell therapy. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2014, 1840, 378-386.	2.4	72
90	Live-cell fluorescent microscopy platforms for real-time monitoring of polyplex-cell interaction: Basic guidelines. <i>Methods</i> , 2014, 68, 300-307.	3.8	10

#	ARTICLE	IF	CITATIONS
91	Just so stories: The random acts of anti-cancer nanomedicine performance. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2014, 10, 1661-1666.	3.3	69
92	The Role of Complement in Antibody Therapy for Infectious Diseases. <i>Microbiology Spectrum</i> , 2014, 2, .	3.0	8
93	Anatomical and Physicochemical Factors Controlling Nanoparticle Pharmacokinetics. <i>Frontiers in Nanobiomedical Research</i> , 2014, , 31-44.	0.1	1
94	Theranostics. , 2014, , 1-3.		2
95	Uptake and Intracellular Trafficking of Nanocarriers. <i>Fundamental Biomedical Technologies</i> , 2014, , 117-138.	0.2	2
96	Reciprocity in the Developmental Regulation of Aquaporins 1, 3 and 5 during Pregnancy and Lactation in the Rat. <i>PLoS ONE</i> , 2014, 9, e106809.	2.5	12
97	Defining and characterizing non-biological complex drugs (NBCDs) – Is size enough? The case for liposomal doxorubicin generics (–liposomal nanosimilars–™) for injection. <i>GaBI Journal</i> , 2014, 3, 56-57.	0.3	5
98	High resolution respirometry analysis of polyethylenimine-mediated mitochondrial energy crisis and cellular stress: Mitochondrial proton leak and inhibition of the electron transport system. <i>Biochimica Et Biophysica Acta - Bioenergetics</i> , 2013, 1827, 1213-1225.	1.0	63
99	Nanomedicine and the complement paradigm. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2013, 9, 458-460.	3.3	68
100	Complement monitoring of Pluronic 127 gel and micelles: Suppression of copolymer-mediated complement activation by elevated serum levels of HDL, LDL, and apolipoproteins AI and B-100. <i>Journal of Controlled Release</i> , 2013, 170, 167-174.	9.9	43
101	Surfactant-mediated complement activation in beagle dogs. <i>International Immunopharmacology</i> , 2013, 17, 33-34.	3.8	7
102	Lactate Dehydrogenase Assay for Assessment of Polycation Cytotoxicity. <i>Methods in Molecular Biology</i> , 2013, 948, 13-22.	0.9	42
103	Structural profiling and biological performance of phospholipid–hyaluronan functionalized single-walled carbon nanotubes. <i>Journal of Controlled Release</i> , 2013, 170, 295-305.	9.9	26
104	Single-Walled Carbon Nanotube Surface Control of Complement Recognition and Activation. <i>ACS Nano</i> , 2013, 7, 1108-1119.	14.6	110
105	Complement activation by PEG-functionalized multi-walled carbon nanotubes is independent of PEG molecular mass and surface density. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2013, 9, 469-473.	3.3	38
106	Genetically engineered T cells bearing chimeric nanoconstructed receptors harboring TAG-72-specific camelid single domain antibodies as targeting agents. <i>Cancer Letters</i> , 2013, 334, 237-244.	7.2	64
107	Combined Fluorimetric Caspase 3/7 Assay and Bradford Protein Determination for Assessment of Polycation-Mediated Cytotoxicity. <i>Methods in Molecular Biology</i> , 2013, 948, 23-33.	0.9	1
108	The Possible –Proton Sponge –Effect of Polyethylenimine (PEI) Does Not Include Change in Lysosomal pH. <i>Molecular Therapy</i> , 2013, 21, 149-157.	8.2	593

#	ARTICLE	IF	CITATIONS
109	Dysfunctional oxidative phosphorylation makes malignant melanoma cells addicted to glycolysis driven by the V600EBRAF oncogene. <i>Oncotarget</i> , 2013, 4, 584-599.	1.8	166
110	Heavy Chain Only Antibodies: A New Paradigm in Personalized HER2+ Breast Cancer Therapy. <i>BiolImpacts</i> , 2013, 3, 1-4.	1.5	23
111	Total Internal Reflection Fluorescence (TIRF) Microscopy for Real-Time Imaging of Nanoparticle-Cell Plasma Membrane Interaction. , 2012, 906, 473-482.		10
112	Complement Sensing of Nanoparticles and Nanomedicines. <i>ACS Symposium Series</i> , 2012, , 365-382.	0.5	11
113	Nanotechnology: from fundamental concepts to clinical applications for healthy aging. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2012, 8, S1-S4.	3.3	8
114	Particulate Systems for Targeting of Macrophages: Basic and Therapeutic Concepts. <i>Journal of Innate Immunity</i> , 2012, 4, 509-528.	3.8	66
115	Polymeric particulate technologies for oral drug delivery and targeting: a pathophysiological perspective. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2012, 8, S5-S20.	3.3	76
116	PEGylated Nanoparticles Bind to and Alter Amyloid-Beta Peptide Conformation: Toward Engineering of Functional Nanomedicines for Alzheimer's Disease. <i>ACS Nano</i> , 2012, 6, 5897-5908.	14.6	164
117	Polyethylenimine-mediated impairment of mitochondrial membrane potential, respiration and membrane integrity: Implications for nucleic acid delivery and gene therapy. <i>Mitochondrion</i> , 2012, 12, 162-168.	3.4	46
118	Perspectives on carbon nanotube-mediated adverse immune effects. <i>Advanced Drug Delivery Reviews</i> , 2012, 64, 1700-1705.	13.7	51
119	Genomic perspectives in inter-individual adverse responses following nanomedicine administration: The way forward. <i>Advanced Drug Delivery Reviews</i> , 2012, 64, 1385-1393.	13.7	44
120	Nanotechnology: From fundamental concepts to clinical applications for healthy aging. <i>Maturitas</i> , 2012, 73, 1-4.	2.4	4
121	Polymeric particulate technologies for oral drug delivery and targeting: A pathophysiological perspective. <i>Maturitas</i> , 2012, 73, 5-18.	2.4	34
122	Factors Controlling Nanoparticle Pharmacokinetics: An Integrated Analysis and Perspective. <i>Annual Review of Pharmacology and Toxicology</i> , 2012, 52, 481-503.	9.4	477
123	Complement system and the brain: Selected pathologies and avenues toward engineering of neurological nanomedicines. <i>Journal of Controlled Release</i> , 2012, 161, 283-289.	9.9	24
124	Reshaping the Future of Nanopharmaceuticals: <i>Ad ludicium</i> . <i>ACS Nano</i> , 2011, 5, 8454-8458.	14.6	90
125	Transformation of structurally diverse steroidal analogues by the fungus <i>Corynespora cassiicola</i> CBS 161.60 results in generation of 8 β -monohydroxylated metabolites with evidence in favour of 8 β -hydroxylation through inverted binding in the 9 α -hydroxylase. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> . 2011, 1811, 1054-1061.	2.4	12
126	Functionalization with ApoE-derived peptides enhances the interaction with brain capillary endothelial cells of nanoliposomes binding amyloid-beta peptide. <i>Journal of Biotechnology</i> , 2011, 156, 341-346.	3.8	92

#	ARTICLE	IF	CITATIONS
127	Nanotechnologies for Alzheimer's disease: diagnosis, therapy, and safety issues. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2011, 7, 521-540.	3.3	240
128	Bionanotechnologies for treatment and diagnosis of Alzheimer's disease. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2011, 7, 515-518.	3.3	17
129	Combined MUC1-specific nanobody-tagged PEG-polyethylenimine polyplex targeting and transcriptional targeting of tBid transgene for directed killing of MUC1 over-expressing tumour cells. <i>Journal of Controlled Release</i> , 2011, 156, 85-91.	9.9	62
130	Hyaluronan-coated nanoparticles: The influence of the molecular weight on CD44-hyaluronan interactions and on the immune response. <i>Journal of Controlled Release</i> , 2011, 156, 231-238.	9.9	204
131	Biological targeting and innovative therapeutic interventions with phage-displayed peptides and structured nucleic acids (aptamers). <i>Current Opinion in Biotechnology</i> , 2011, 22, 832-838.	6.6	19
132	Material properties in complement activation. <i>Advanced Drug Delivery Reviews</i> , 2011, 63, 1000-1007.	13.7	230
133	Complement monitoring of nanomedicines and implants. <i>Advanced Drug Delivery Reviews</i> , 2011, 63, 963-964.	13.7	5
134	Complement activation cascade triggered by PEG-PL engineered nanomedicines and carbon nanotubes: The challenges ahead. <i>Journal of Controlled Release</i> , 2010, 146, 175-181.	9.9	157
135	Cationic carriers of genetic material and cell death: A mitochondrial tale. <i>Biochimica Et Biophysica Acta - Bioenergetics</i> , 2010, 1797, 1203-1209.	1.0	117
136	Complement monitoring of carbon nanotubes. <i>Nature Nanotechnology</i> , 2010, 5, 382-382.	31.5	26
137	Complement monitoring of carbon nanotubes. <i>Nature Nanotechnology</i> , 2010, 5, 382-383.	31.5	13
138	Polycation cytotoxicity: a delicate matter for nucleic acid therapy—focus on polyethylenimine. <i>Soft Matter</i> , 2010, 6, 4001.	2.7	193
139	Engineering Liposomes and Nanoparticles for Biological Targeting. <i>Advances in Biochemical Engineering/Biotechnology</i> , 2010, 125, 251-280.	1.1	33
140	Distinct Polymer Architecture Mediates Switching of Complement Activation Pathways at the Nanosphere-Serum Interface: Implications for Stealth Nanoparticle Engineering. <i>ACS Nano</i> , 2010, 4, 6629-6638.	14.6	263
141	Hypersensitivity Reactions to Nanomedicines: Causative Factors and Optimization of Design Parameters. , 2010, , 225-237.		2
142	Chapter 3. Nanoparticle Engineering for the Lymphatic System and Lymph Node Targeting. <i>RSC Nanoscience and Nanotechnology</i> , 2010, , 81-97.	0.2	4
143	Tunable 3D and 2D polystyrene nanoparticle assemblies using surface wettability, low volume fraction and surfactant effects. <i>Nanotechnology</i> , 2009, 20, 025604.	2.6	14
144	Complement-mediated tumour growth: Implications for cancer nanotechnology and nanomedicines. <i>Molecular Immunology</i> , 2009, 46, 1571-1572.	2.2	19

#	ARTICLE	IF	CITATIONS
145	Factors Controlling Pharmacokinetics of Intravenously Injected Nanoparticulate Systems. , 2009, , 267-282.		3
146	Liposome triggering of innate immune responses: A perspective on benefits and adverse reactions. Journal of Liposome Research, 2009, 19, 85-90.	3.3	104
147	Complement: Alive and Kicking Nanomedicines. Journal of Biomedical Nanotechnology, 2009, 5, 364-372.	1.1	71
148	<l>A Special Issue on</l> Nano- and Micro-Technologies for Biological Targeting, Tracking, Imaging and Sensing. Journal of Biomedical Nanotechnology, 2009, 5, 611-613.	1.1	1
149	Liposome-Mediated Triggering of Complement Cascade. Journal of Liposome Research, 2008, 18, 195-209.	3.3	72
150	Complement activation by PEGylated single-walled carbon nanotubes is independent of C1q and alternative pathway turnover. Molecular Immunology, 2008, 45, 3797-3803.	2.2	122
151	Poly(ethylene glycol)s generate complement activation products in human serum through increased alternative pathway turnover and a MASP-2-dependent process. Molecular Immunology, 2008, 46, 225-232.	2.2	231
152	Enhanced lymph node retention of subcutaneously injected IgG1-PEG2000-liposomes through pentameric IgM antibody-mediated vesicular aggregation. Biochimica Et Biophysica Acta - Biomembranes, 2008, 1778, 51-55.	2.6	24
153	Lymphatic targeting of immuno-PEG-liposomes: Evaluation of antibody-coupling procedures on lymph node macrophage uptake. Journal of Drug Targeting, 2008, 16, 586-590.	4.4	13
154	Critical issues in site-specific targeting of solid tumours: the carrier, the tumour barriers and the bioavailable drug. Expert Opinion on Drug Delivery, 2008, 5, 205-219.	5.0	34
155	Polymeric Nanocarriers for siRNA Delivery: Challenges and Future Prospects. Journal of Biomedical Nanotechnology, 2008, 4, 258-275.	1.1	27
156	Particulate nanomedicine in the footsteps of platelet homing. Nanomedicine, 2007, 2, 381-384.	3.3	1
157	Ordering of Binary Polymeric Nanoparticles on Hydrophobic Surfaces Assembled from Low Volume Fraction Dispersions. Journal of the American Chemical Society, 2007, 129, 13390-13391.	13.7	36
158	Modification of the Stewart biphasic colorimetric assay for stable and accurate quantitative determination of Pluronic and Tetronic block copolymers for application in biological systems. Analytical Biochemistry, 2007, 361, 287-293.	2.4	21
159	Methylation of the phosphate oxygen moiety of phospholipidâ€methoxy(polyethylene glycol) conjugate prevents PEGylated liposomeâ€mediated complement activation and anaphylatoxin production. FASEB Journal, 2006, 20, 2591-2593.	0.5	185
160	Concentration Dependent Structural Ordering of Poloxamine 908 on Polystyrene Nanoparticles and Their Modulatory Role on Complement Consumption. Journal of Nanoscience and Nanotechnology, 2006, 6, 3126-3133.	0.9	58
161	The effect of methoxy-PEG chain length and molecular architecture on lymph node targeting of immuno-PEG liposomes. Biomaterials, 2006, 27, 136-144.	11.4	73
162	Activation of the Human Complement System by Cholesterol-Rich and PEGylated Liposomesâ€Modulation of Cholesterol-Rich Liposome-Mediated Complement Activation by Elevated Serum LDL and HDL Levels. Journal of Liposome Research, 2006, 16, 167-174.	3.3	61

#	ARTICLE	IF	CITATIONS
163	Particulate nanomedicines†. Advanced Drug Delivery Reviews, 2006, 58, 1451-1455.	13.7	43
164	Recent Developments in Polymeric Nanoparticle Engineering and Their Applications in Experimental and Clinical Oncology. Anti-Cancer Agents in Medicinal Chemistry, 2006, 6, 553-561.	1.7	65
165	Polymeric Nanoparticles as Drug Carriers and Controlled Release Implant Devices. , 2006, , 29-42.		9
166	A two-stage poly(ethylenimine)-mediated cytotoxicity: implications for gene transfer/therapy. Molecular Therapy, 2005, 11, 990-995.	8.2	967
167	Editorial [Hot Topic: Lipid-Based Nanosystems and Complexes in Experimental and Clinical Therapeutics (Guest Editors: A. Agrawal and S.M. Moghimi)]. Current Drug Delivery, 2005, 2, 295-295.	1.6	8
168	Low and high molecular weight poly(L-lysine)s/poly(L-lysine)â€‘DNA complexes initiate mitochondrialâ€‘mediated apoptosis differently. FEBS Letters, 2005, 579, 6191-6198.	2.8	109
169	Nanomedicine: current status and future prospects. FASEB Journal, 2005, 19, 311-330.	0.5	1,732
170	Cellular Distribution of Nonionic Micelles. Science, 2004, 303, 626-628.	12.6	57
171	Causative factors behind poloxamer 188 (Pluronic F68, FloCorâ„¢)-induced complement activation in human sera. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2004, 1689, 103-113.	3.8	106
172	Synthetic polymers in 21st century therapeutics: the way forward â–¼. Drug Discovery Today, 2003, 8, 154-156.	6.4	5
173	Modulation of lymphatic distribution of subcutaneously injected poloxamer 407â€‘coated nanospheres: the effect of the ethylene oxide chain configuration. FEBS Letters, 2003, 540, 241-244.	2.8	61
174	Real-time evidence of surface modification at polystyrene lattices by poloxamine 908 in the presence of serum: in vivo conversion of macrophage-prone nanoparticles to stealth entities by poloxamine 908. FEBS Letters, 2003, 547, 177-182.	2.8	33
175	Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. Progress in Lipid Research, 2003, 42, 463-478.	11.6	1,084
176	Nanoparticle-mediated gene delivery to tumour neovasculature. Trends in Molecular Medicine, 2003, 9, 2-4.	6.7	47
177	Exploitation of Macrophage Clearance Functions In Vivo. Handbook of Experimental Pharmacology, 2003, , 41-54.	1.8	4
178	Endothelial Cells as Therapeutic Targets in Cancer: New Biology and Novel Delivery Systems. Critical Reviews in Therapeutic Drug Carrier Systems, 2003, 20, 139-152.	2.2	14
179	LIPOSOME RECOGNITION BY RESIDENT AND NEWLY RECRUITED MURINE LIVER MACROPHAGES. Journal of Liposome Research, 2002, 12, 67-70.	3.3	9
180	PEGylation of microspheres generates a heterogeneous population of particles with differential surface characteristics and biological performance. FEBS Letters, 2002, 532, 338-344.	2.8	131

#	ARTICLE	IF	CITATIONS
181	Chemical camouflage of nanospheres with a poorly reactive surface: towards development of stealth and target-specific nanocarriers. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2002, 1590, 131-139.	4.1	88
182	Modulation of murine liver macrophage clearance of liposomes by diethylstilbestrol. The effect of vesicle surface charge and a role for the complement receptor Mac-1 (CD11b/CD18) of newly recruited macrophages in liposome recognition. <i>Journal of Controlled Release</i> , 2002, 78, 55-65.	9.9	32
183	Therapeutic synthetic polymers: a game of Russian roulette?. <i>Drug Discovery Today</i> , 2002, 7, 998-1001.	6.4	80
184	Recognition and clearance of methoxypoly(ethyleneglycol)2000-grafted liposomes by macrophages with enhanced phagocytic capacity Implications in experimental and clinical oncology. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2001, 1526, 227-229.	2.4	26
185	Recognition by macrophages and liver cells of opsonized phospholipid vesicles and phospholipid headgroups. , 2001, 18, 1-8.		133
186	Capture of Stealth Nanoparticles by the Body's Defences. <i>Critical Reviews in Therapeutic Drug Carrier Systems</i> , 2001, 18, 24.	2.2	125
187	Long-circulating and target-specific nanoparticles: theory to practice. <i>Pharmacological Reviews</i> , 2001, 53, 283-318.	16.0	2,472
188	Capture of stealth nanoparticles by the body's defences. <i>Critical Reviews in Therapeutic Drug Carrier Systems</i> , 2001, 18, 527-50.	2.2	37
189	Recent advances in cellular, sub-cellular and molecular targeting. <i>Advanced Drug Delivery Reviews</i> , 2000, 41, 129-133.	13.7	37
190	Poloxamers and poloxamines in nanoparticle engineering and experimental medicine. <i>Trends in Biotechnology</i> , 2000, 18, 412-420.	9.3	351
191	Hormonal Control of Macrophage Phagocytosis of Phospholipid Vesicles. <i>Journal of Liposome Research</i> , 2000, 10, 409-417.	3.3	1
192	Subcutaneous and intravenous delivery of diagnostic agents to the lymphatic system: applications in lymphoscintigraphy and indirect lymphography. <i>Advanced Drug Delivery Reviews</i> , 1999, 37, 295-312.	13.7	129
193	Re-establishing the long circulatory behaviour of poloxamine-coated particles after repeated intravenous administration: applications in cancer drug delivery and imaging. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 1999, 1472, 399-403.	2.4	26
194	Serum-mediated recognition of liposomes by phagocytic cells of the reticuloendothelial system – The concept of tissue specificity. <i>Advanced Drug Delivery Reviews</i> , 1998, 32, 45-60.	13.7	219
195	Recent Developments and Limitations of Poloxamine-Coated Long-Circulating Particles in Experimental Drug Delivery. , 1998, , 263-274.		0
196	A Single Dose of Intravenously Injected Poloxamine-Coated Long-Circulating Particles Triggers Macrophage Clearance of Subsequent Doses in Rats. <i>Clinical Science</i> , 1997, 93, 371-379.	4.3	54
197	Prolonging the circulation time and modifying the body distribution of intravenously injected polystyrene nanospheres by prior intravenous administration of poloxamine-908. A 'hepatic-blockade' event or manipulation of nanosphere surface in vivo?. <i>Biochimica Et Biophysica Acta - General Subjects</i> . 1997. 1336. 1-6.	2.4	37
198	Activation of the mononuclear phagocyte system by poloxamine 908: its implications for targeted drug delivery. <i>Pharmaceutical Research</i> , 1997, 14, 1629-1633.	3.5	4

#	ARTICLE	IF	CITATIONS
199	Altered tissue-specific opsonic activities and opsono-recognition of liposomes in tumour-bearing rats. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 1996, 1285, 56-64.	2.6	12
200	Advanced colloid-based systems for efficient delivery of drugs and diagnostic agents to the lymphatic tissues. <i>Progress in Biophysics and Molecular Biology</i> , 1996, 65, 221-249.	2.9	58
201	Poloxamer-188 Revisited: a Potentially Valuable Immune Modulator?. <i>Journal of the National Cancer Institute</i> , 1996, 88, 766-768.	6.3	39
202	Mechanisms regulating body distribution of nanospheres conditioned with pluronic and tetronic block co-polymers. <i>Advanced Drug Delivery Reviews</i> , 1995, 16, 183-193.	13.7	71
203	Exploiting bone marrow microvascular structure for drug delivery and future therapies. <i>Advanced Drug Delivery Reviews</i> , 1995, 17, 61-73.	13.7	84
204	Mechanisms of splenic clearance of blood cells and particles: towards development of new splenotropic agents. <i>Advanced Drug Delivery Reviews</i> , 1995, 17, 103-115.	13.7	126
205	Surface engineered nanospheres with enhanced drainage into lymphatics and uptake by macrophages of the regional lymph nodes. <i>FEBS Letters</i> , 1994, 344, 25-30.	2.8	129
206	Organ-Specific Targeting of Synthetic and Natural Drug Carriers. <i>Advances in Molecular and Cell Biology</i> , 1994, 9, 263-282.	0.1	4
207	Innovations in avoiding particle clearance from blood by Kupffer cells: cause for reflection. <i>Critical Reviews in Therapeutic Drug Carrier Systems</i> , 1994, 11, 31-59.	2.2	33
208	Microspheres for targeting drugs to specific body sites. <i>Journal of Controlled Release</i> , 1993, 24, 157-163.	9.9	83
209	Current progress and future prospects of liposomes in dermal drug delivery. <i>Journal of Microencapsulation</i> , 1993, 10, 155-162.	2.8	19
210	An investigation of the filtration capacity and the fate of large filtered sterically-stabilized microspheres in rat spleen. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 1993, 1157, 233-240.	2.4	151
211	Coating particles with a block co-polymer (poloxamine-908) suppresses opsonization but permits the activity of dysopsonins in the serum. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 1993, 1179, 157-165.	4.1	227
212	Effect of Splenic Congestion Associated with Haemolytic Anaemia on Filtration of α -Spleen-Homing TM Microspheres. <i>Clinical Science</i> , 1993, 84, 605-609.	4.3	16
213	Serum factors that regulate phagocytosis of liposomes by Kupffer cells. <i>Biochemical Society Transactions</i> , 1993, 21, 128S-128S.	3.4	25
214	Enhanced hepatic clearance of intravenously administered sterically stabilized microspheres in zymosan-stimulated rats. <i>Journal of Leukocyte Biology</i> , 1993, 54, 513-517.	3.3	50
215	Opsonophagocytosis of liposomes by peritoneal macrophages and bone marrow reticuloendothelial cells. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 1992, 1135, 269-274.	4.1	57
216	The polyoxyethylene/polyoxypropylene block co-polymer Poloxamer [®] 407 selectively redirects intravenously injected microspheres to sinusoidal endothelial cells of rabbit bone marrow. <i>FEBS Letters</i> , 1992, 305, 62-66.	2.8	155

#	ARTICLE	IF	CITATIONS
217	Differences in the molecular weight profile of poloxamer 407 affect its ability to redirect intravenously administered colloids to the bone marrow. International Journal of Pharmaceutics, 1992, 83, 273-276.	5.2	22
218	Non-phagocytic uptake of intravenously injected microspheres in rat spleen: Influence of particle size and hydrophilic coating. Biochemical and Biophysical Research Communications, 1991, 177, 861-866.	2.1	279
219	The effect of block co-polymers on the uptake of model polystyrene microspheres by Kupffer cells - in vitro and in vivo studies. Biochemical Society Transactions, 1991, 19, 329S-329S.	3.4	19
220	The effect of poloxamer-407 on liposome stability and targeting to bone marrow: comparison with polystyrene microspheres. International Journal of Pharmaceutics, 1991, 68, 121-126.	5.2	57
221	Calcium as a possible modulator of Kupffer cell phagocytic function by regulating liver-specific opsonic activity. Biochimica Et Biophysica Acta - Biomembranes, 1990, 1028, 304-308.	2.6	18
222	Tissue Specific Serum Opsonins and Phagocytosis of Liposomes. , 1990, , 87-94.		4
223	Physiopathological and physicochemical considerations in targeting of colloids and drug carriers to the bone marrow. Critical Reviews in Therapeutic Drug Carrier Systems, 1990, 7, 187-209.	2.2	6
224	Differential properties of organ-specific serum opsonins for liver and spleen macrophages. Biochimica Et Biophysica Acta - Biomembranes, 1989, 984, 379-383.	2.6	82
225	Serum opsonins and phagocytosis of saturated and unsaturated phospholipid liposomes. Biochimica Et Biophysica Acta - Biomembranes, 1989, 984, 384-387.	2.6	110
226	Tissue specific opsonins for phagocytic cells and their different affinity for cholesterol-rich liposomes. FEBS Letters, 1988, 233, 143-147.	2.8	138
227	The Innate Immune Responses, Adjuvants and Delivery Systems. , 0, , 113-127.		5
228	The Role of Complement in Antibody Therapy for Infectious Diseases. , 0, , 63-74.		0